260 related articles for article (PubMed ID: 18570742)
1. [Efficiency of prevention and treatment of veno-occlusive disease of the liver after allogeneic stem cell transplantation].
Dong M; Lin Q; Wu XY
Ai Zheng; 2008 Jun; 27(6):646-9. PubMed ID: 18570742
[TBL] [Abstract][Full Text] [Related]
2. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
Kalayoglu-Besisik S; Yenerel MN; Caliskan Y; Ozturk S; Besisik F; Sargin D
Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
[TBL] [Abstract][Full Text] [Related]
3. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.
Tanikawa S; Mori S; Ohhashi K; Akiyama H; Sasaki T; Kaku H; Hiruma K; Matsunaga T; Morita T; Sakamaki H
Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389
[TBL] [Abstract][Full Text] [Related]
4. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.
Song JS; Seo JJ; Moon HN; Ghim T; Im HJ
J Korean Med Sci; 2006 Oct; 21(5):897-903. PubMed ID: 17043426
[TBL] [Abstract][Full Text] [Related]
6. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
[TBL] [Abstract][Full Text] [Related]
7. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
Qureshi A; Marshall L; Lancaster D
Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
[TBL] [Abstract][Full Text] [Related]
8. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
Moscardó F; Sanz GF; de La Rubia J; Jiménez C; Saavedra S; Regadera A; Andreu R; García I; Plumé G; Martínez J; Martín G; Jarque I; Sanz MA
Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110
[TBL] [Abstract][Full Text] [Related]
9. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.
Schriber J; Milk B; Shaw D; Christiansen N; Baer M; Slack J; Tezcan H; Wetzler M; Herzig G
Bone Marrow Transplant; 1999 Dec; 24(12):1311-4. PubMed ID: 10627640
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
Park SH; Lee MH; Lee H; Kim HS; Kim K; Kim WS; Jung CW; Im YH; Yoon SS; Kang WK; Park K; Park CH; Kim SW
Bone Marrow Transplant; 2002 Jan; 29(2):137-43. PubMed ID: 11850708
[TBL] [Abstract][Full Text] [Related]
11. Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.
Heying R; Nürnberger W; Spiekerkötter U; Göbel U
Bone Marrow Transplant; 1998 May; 21(9):947-9. PubMed ID: 9613790
[TBL] [Abstract][Full Text] [Related]
12. [Low dose heparin for the prevention of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation].
Chen J; Zhu KE; Zhang T; Zhong J; Chen ST; Zeng HL
Zhonghua Nei Ke Za Zhi; 2007 Feb; 46(2):140-2. PubMed ID: 17445443
[TBL] [Abstract][Full Text] [Related]
13. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
14. Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation.
Mori T; Aisa Y; Shimizu T; Yamazaki R; Mihara A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Am J Hematol; 2007 Sep; 82(9):838-9. PubMed ID: 17506069
[TBL] [Abstract][Full Text] [Related]
15. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation.
Pihusch M; Wegner H; Goehring P; Salat C; Pihusch V; Andreesen R; Kolb HJ; Holler E; Pihusch R
Bone Marrow Transplant; 2005 Oct; 36(7):631-7. PubMed ID: 16062176
[TBL] [Abstract][Full Text] [Related]
16. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
Chalandon Y; Roosnek E; Mermillod B; Newton A; Ozsahin H; Wacker P; Helg C; Chapuis B
Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of low-dose heparin and prostaglandin E1 in the prevention of hepatic veno-occlusive disease after allogenic hematopoietic stem cell transplantation in children with beta-thalassemia major].
Sun X; Hao WG; Liu S; Xia T; Liao C
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug; 9(4):343-6. PubMed ID: 17706036
[TBL] [Abstract][Full Text] [Related]
18. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.
Carreras E; Díaz-Beyá M; Rosiñol L; Martínez C; Fernández-Avilés F; Rovira M
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1713-20. PubMed ID: 21708110
[TBL] [Abstract][Full Text] [Related]
19. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
Simon M; Hahn T; Ford LA; Anderson B; Swinnich D; Baer MR; Bambach B; Bernstein SH; Bernstein ZP; Czuczman MS; Slack JL; Wetzler M; Herzig G; Schriber J; McCarthy PL
Bone Marrow Transplant; 2001 Mar; 27(6):627-33. PubMed ID: 11319593
[TBL] [Abstract][Full Text] [Related]
20. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome.
Lee SH; Yoo KH; Sung KW; Koo HH; Kwon YJ; Kwon MM; Park HJ; Park BK; Kim YY; Park JA; Im HJ; Seo JJ; Kang HJ; Shin HY; Ahn HS
Bone Marrow Transplant; 2010 Aug; 45(8):1287-93. PubMed ID: 20010866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]